CDA | Evidence Driven
CDA | Evidence Driven

Inlyta for metastatic renal cell carcinoma (mRCC) - Details

Details

Files
Generic Name:
Axitinib
Project Status:
Complete
Therapeutic Area:
Metastatic Renal Cell Carcinoma
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Inlyta
Project Line:
Reimbursement Review
Project Number:
PC0013-000
Performance Metric:
N/A — Predated performance metrics
Strength:
1mg and 5mg
Tumour Type:
Genitourinary
Indications:
Metastatic Renal Cell Carcinoma
Funding Request:
For the treatment of patients with metastatic renal cell carcinoma (RCC) of clear histology after failure of prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib
Review Status:
Complete
Sponsor:
Pfizer Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued:

Note: The pCODR Provincial Advisory Group, PAG, has submitted a Request for Advice for this drug & indication on April 18, 2017. Please see the RFA: Inlyta for Metastatic Renal Cell Carcinoma details page for more information: https://www.cadth.ca/rfa-inlyta-metastatic-renal-cell-carcinoma.

Files

Provincial Funding Summary View PDF
Axitinib (Inlyta) for mRCC - pERC Final Recommendation Final Recommendation March 7, 2013 View PDF
Axitinib (Inlyta) for mRCC - Final Clinical Guidance Report Guidance Reports March 7, 2013 View PDF
Axitinib (Inlyta) for mRCC - Final Economic Guidance Report Guidance Reports March 7, 2013 View PDF
Axitinib (Inlyta) for mRCC - pERC Initial Recommendation Initial Recommendation January 14, 2013 View PDF
Axitinib (Inlyta) for mRCC - PAG Feedback on Initial Recommendation Feedback March 7, 2013 View PDF
Axitinib (Inlyta) for mRCC - Manufacturer (Pfizer Canada Inc.) Feedback on Initial Recommendation Feedback March 7, 2013 View PDF
Axitinib (Inlyta) for mRCC - Patient Advocacy Group (KCC) Feedback on Initial Recommendation Feedback March 7, 2013 View PDF
Axitinib (Inlyta) for mRCC - Patient Advocacy Group (KCC) COI Declarations Feedback March 7, 2013 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : March 22, 2013